Advancements in radiotherapy have contributed to new treatment strategies for EGFR-mutated NSCLC with Oligo-PD owing to the availability of stereotactic radiotherapy (SRT), an advanced radiotherapy modality with high local tumor control rates. The gene discussed is EGFR; the disease is neoplasm.